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Abstract
Background: The aim of this study is to determine the prevalence of anti-HCV among injecting drug users (IDUs) in 
Lebanon, to establish the current prevalence of HCV genotypes in this population and to determine whether 
demographic characteristics and behavioral variables differ between participants who were HCV-RNA positive and 
those who were HCV-RNA negative or between the different genotypes. Participants were recruited using respondent-
driven sampling method. The blood samples were collected as dried blood spots and then eluted to be tested for HCV, 
HBV and HIV by ELISA. Anti-HCV positive samples were subjected to RNA extraction followed by qualitative detection 
and genotyping.
Results: Among 106 IDUs, 56 (52.8%) were anti-HCV-positive. The two groups did not differ in terms of age, marital 
status, and nationality. As for the behavioral variable, there was a trend of increased risky behaviors among the HCV-
RNA positive group as compared to the HCV-RNA negative group but none of the variables reached statistical 
significance. Half (50%) of the 56 anti-HCV-positive were HCV-RNA positive. Genotype 3 was the predominant one 
(57.1%) followed by genotype 1 (21%) and genotype 4 (18%).
Conclusions: The predominance of genotype 3 seems to be the predominant genotype among IDUs in Lebanon, a 
situation similar to that among IDUs in Western Europe. This study provides a base-line against possible future radical 
epidemiological variant that might occur in IDUs.
Background
The prevalence of HCV antibody (anti-HCV) among
intravenous drug users (IVDUs) who share injecting
equipment exceeds 50% [1,2]. This has now become a
critical public health threat [3]. The lack of availability of
an effective vaccine allowed education programs to be the
most suitable interventions in the control of HCV spread
[4,5].
Hepatitis C virus has been classified into 6 major geno-
types (1-6) and into several subtypes (a, b, c etc) [6] and
additional genotypes have been recently proposed [7,8].
The genotypes have a geographically distinct distribution
[9,10] which carries important implications such as treat-
ment decisions, possible transmission route and vaccine
development. For example the response to therapy
observed in patients infected with genotypes 1 and 4 is
lower than that infected with genotypes 2 and 3 [11,12].
Genotype 3a was shown to be more common in Europe
among young injecting drug users, compared to genotype
1b which is associated with transfusion-related HCV
[13]. Recently we have shown genotype 4 to be the pre-
dominant genotype among HCV-infected Lebanese
patients (34.2%-53.3%) [10].
The aim of this study is to determine the prevalence of
anti-HCV among injecting drug users (IDUs) in Lebanon,
to establish the current prevalence of HCV genotypes in
this population and to determine whether demographic
characteristics and behavioral variables differ between
participants who were HCV-RNA positive and those who
were HCV-RNA negative or between the different geno-
types.
Methods
Study Population and Sampling Methods
Participants included in this study were part of a bio-
behavioral surveillance study done to assess HIV preva-
lence among four vulnerable groups (men who have sex
with men, injecting drug users, female sex workers, and
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prisoners). Two well established Lebanese non-govern-
mental organizations (NGOs) that work with IDUs
helped in the study.
Participants in this study were recruited using a rela-
tively new technique entitled respondent-driven sam-
pling (RDS) that has been shown to be effective in
reaching difficult to reach or invisible populations for
which there is not sampling-frame [14]. A total of 106 eli-
gible IDUs participated in the main study and all were
males. After obtaining informed consent, participants
completed the questionnaire and an HIV rapid test were
offered in addition to proper pretest and post test coun-
seling.
Laboratory Methods
Sample collection
Peripheral blood was collected by a finger prick with a
single use Lancet and then blotted onto a high quality fil-
ter paper (Schleicher & Schuell 903). The blood spot was
allowed to air dry to be used as a dried blood spot (DBS)
for further testing at the Molecular Biology Research
Laboratory at the Faculty of Health Sciences, American
University of Beirut (AUB).
Elution procedure
For each serological test, one DBS disc was cut and
placed in the well of a flat-bottomed uncoated micro
plate. The blood was then eluted as described previously
by Parker and Gublit [15].
Anti-HCV detection and RNA extraction
Eluates were tested for anti-HCV by ELISA using a modi-
fied protocol for Ortho HCV 3.0 SAVe (Ortho Clinical
Diagnostics, Johnson & Johnson). Anti-HCV positive
DBS samples were then subjected to RNA extraction
using QIAamp MiniElute Virus Spin (QIAGEN) for fur-
ther qualitative HCV detection and genotyping.
HCV qualitative detection and HCV genotyping
COBAS AMPLICOR Hepatitis C Virus Test, version 2.0
(v2.0) was used for qualitative in vitro diagnostic HCV
detection in the RNA extracted samples using COBAS
AMPLICOR Analyzer (Roche). Qualitatively positive
HCV aliquots of denatured amplicon by Cobas Amplicor
were genotyped using a single LINEAR ARRAY HCV
Genotyping strip (LINEAR ARRAY Hepatitis C Virus
Genotyping Test - Roche) which is coated with a series of
oligonucleotide probes specific for various HCV geno-
types.
Statistical Analysis
Descriptive statistics including means and standard devi-
ation and frequency distributions were computed for
demographic variables and behavioral variables. Compar-
isons between HCV-RNA positive and HCV-RNA nega-
tive groups were performed using the Chi-squared test
for categorical variables (for examples, Sharing needles,
marital status, imprisonment, and having a tattoo) and t-
test for continuous variables (for example age). Signifi-
cance was set at the 5% level. All analysis were done using
SPSS version 16.0 (Chicago, Illinois, USA).
Results
Only 28 (50%) of the 56 anti-HCV-positive were HCV-
RNA positive. Characteristics and behaviors of those who
were HCV-RNA positive and HCV-RNA negative are
summarized in Table 1. The average age of the partici-
pants was 40 years. Almost all participant were Lebanese
(96%) and a high proportion of them were ever married
(61%). The two groups did not differ in terms of age, mar-
ital status, and nationality. As for the behavioral variable,
there was a trend of increased risky behaviors (such as
having tattoos, sharing needles and injecting drugs in
prison) among the HCV-RNA positive group as com-
pared to the HCV-RNA negative group but none of the
variables reached statistical significance.
HCV Genotype Distribution
Only HCV genotypes 1, 3 and 4 were detected and one
sample showed mixed genotype (1 and 3). The distribu-
tion of genotypes is shown in Table 2. Genotype 3 was the
predominant (57%) followed by genotype 1 (21%) and
genotype 4 (18%).
Characteristics of the HCV RNA-positive sample pop-
ulation (n = 28) according to their genotype is shown in
Table 3. The one person with a mixed genotype was not
included since no replication is available for comparison
reasons.
Discussion
HCV-RNA positivity (50%) detected in our anti-HCV-
positive IDUs patients is in agreement with similar stud-
ies from different parts of the world including
Europe[2,16], North America[17] and Australia [18]. It
has been recently reported that a statistically significant
linear relationship could be observed between the mean
age and the prevalence of HCV-RNA in IDUs [19]. This
linearity however could not be confirmed in our study
since most of our studied subjects were relatively young
adults and experienced their first injection within roughly
the same period of time.
The distribution of HCV genotypes in our IDUs
showed that HCV genotype 3 was the predominant geno-
type (57.1%) followed by genotype 1 (21.4%) and geno-
type 4 (17.9%). This was surprising and in contrast with
our earlier findings where genotype 4 was the predomi-
nant genotype (47.5%) in Lebanese patients [10]. The
strength of our current data compared to the aforemen-
tioned one is that IDUs were recruited in this study by a
novel technique (RDS) and that they were from different
regions of the country while the earlier study was hospi-Mahfoud et al. Virology Journal 2010, 7:96
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Table 1: Comparing Characteristics and behaviors of those who were HCV-RNA positive to those who were HCV-RNA 
negative
HCV RNA
Variable Positive
(n = 28)
Negative
(n = 28)
p-value
Demographic
• Age (in years)
- Mean ± st dev 40 ± 11 40 ± 13 .98
- Median (min-max) 38 (21-67) 40 (21-63)
• Marital Status .51
- Married 10 (36%) 6 (21%)
- Divorced 4 (14%) 8 (29%)
- Separated 3 (11%) 3 (11%)
- Single 11 (39%) 11 (39%)
• Lebanese Nationality 26 (93%) 27 (96%) >.99
Injecting Risk Behavior
• Ever sharing injecting 
equipments
12 (43%) 9 (32%) .41
• Age first injecting drug 
use
- Mean ± st dev 28 ± 11 28 ± 9 >.99
- Median (min-max) 25 (14-59) 26 (14-53)
Ever Imprisonment 28 (100%) 26 (93%) >.99
Injecting while in prison 4 (14%) 2 (8%) .44
Tattoo 24 (86%) 19 (68%) .11
Table 2: Distribution of HCV Genotypes among Injecting Drug users (IDUs) in Lebanon
Genotype Number %
Genotype I 6 21
Genotype 2 0 0
Genotype 3 16 57
Genotype 4 5 18
Genotype 5 0 0
Genotype 6 0 0
Mixed genotype (1/3) 1 4
TOTAL 28 100Mahfoud et al. Virology Journal 2010, 7:96
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tal-based. The predominance of genotype 3 makes the
situation in Lebanon similar to that among IDUs in
Europe [2,16] and points to the possibility that genotype 3
could have been introduced to our IDUs Population from
Europe. One of the limitations of the study is that the
questionnaire did not address socio-economic factors
such as income, education and mobility among others.
Since IDUs become infected with HCV in the early
phases of drug addiction and most become exposed
repeatedly to the virus through needle-sharing, it is
e x p e c t e d  t h a t  i n f e c t i o n  w i t h  m o r e  t h a n  o n e  g e n o t y p e
would be common [20]. Mixed infections of genotypes
were detected in only one sample in our study (3.6%). The
higher incidence of mixed infections reported by others
could possibly be due to the older age of IDUs in these
studies and hence more multiple exposures to HCV
infection by sharing of injection material.
Data on major HCV genotypes circulating among
injecting drug users in neighboring Middle Eastern coun-
tries is still limited [21,22]. This information would be of
importance in contributing to a regional network for the
surveillance of HCV genotypes in Middle Eastern coun-
tries, an information that could have epidemiological sig-
nificance. Furthermore, our data might also have
therapeutic implications. It has been reported that the
response to therapy in patients infected with genotypes 1
and 4 is lower than that noticed in patients infected with
genotypes 2 and 3 [11,12]. It is believed that appropriate
treatment may play a role in containing the HCV epi-
demic that is now being described in IDUs all over the
world.
Conclusions
Despite the small number of patients investigated, it can
be concluded that genotype 3 seems to be the predomi-
nant genotype among IDUs in Lebanon, a situation simi-
lar to that among IDUs in Western Europe. However, the
authors would like to acknowledge that the sample
method used (RDS) was not random as is the situation for
population-based surveys such as the National Health
and the Examination Survey and thus our findings may or
may not be representative of the entire population of
Table 3: Characteristics of the HCV RNA positive sample population according to their genotypes
HCV Genotypes
Patient Characteristic 1 (n = 6)
N %
3(n = 16)
N %
4 (n = 5)
N %
Demographic
• Age (in years) 44 ± 9 40 ± 13 38 ± 10
- Mean ± st dev 40 (36-60) 37 (21-67) 35 (26-51)
- Median (min-max)
• Marital Status
- Married 3 (50%) 5 (31%) 2 (40%)
- Divorced 1 (17%) 1 (6%) 2 (40%)
- Separated 0 (0%) 3 (19%) 0 (0%)
- Single 2 (33%) 7 (44%) 1 (20%)
• Lebanese Nationality 4 (67%) 16 (100%) 5 (100%)
Injecting Risk Behavior
• Ever sharing injecting 
equipments
3 (50%) 5 (31%) 4 (80%)
• Age first injecting drug 
use
- Mean ± st dev 31 ± 16 29 ± 10 25 ± 13
- Median (min-max) 28 (17-59) 26 (14-52) 20 (17-47)
Ever Imprisonment 6 (100%) 16 (100%) 5 (100%)
Injecting while in prison 1 (17%) 2 (13%) 1 (20%)
Tattoo 4 (67%) 14 (88%) 5 (100%)Mahfoud et al. Virology Journal 2010, 7:96
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IDUs in Lebanon. This study provides a base-line against
possible future radical epidemiological variant that might
occur in IDUs.
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